|
◯ Alpha Helix
2026-09-07
|
| The Alpha Helix Brief · week of 2026-09-07 |
| Quiet week. Nothing new cleared the bar. |
| // TL;DR |
| › Quiet week: nothing new cleared the bar for the corpus. | | › Still worth reading: Semaglutide 13.6–16.6% (NCT05564117); Retatrutide 28.3% (NCT05929066); Cagrilintide 22.7% (NCT05567796). |
|
| 0 new · 0 human · 0 preclinical · 0 regulatory · corpus 24 |
| // Still worth reading |
|
13.6–16.6%
weight reduction
FDA APPROVED Semaglutide · NCT05564117
Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4)
Human · randomized
|
|
28.3%
weight reduction
HUMAN RCT Retatrutide · NCT05929066
Retatrutide in adults with obesity (TRIUMPH-1)
Human · randomized · n=2,339 · 80 weeks
|
|
22.7%
mean weight reduction
HUMAN RCT Cagrilintide · NCT05567796
Cagrilintide-semaglutide in adults with overweight or obesity (REDEFINE 1)
Human · randomized
|
|
Open the Evidence Map
|
Educational summary of published research. Not medical advice.
@alphahelix.research · What the evidence actually says.
Unsubscribe
|